Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call

SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus' third quarter 2017 financial results will be released on Thursday, November 2, 2017 at 4:01 p.m. Eastern Time.  Company management will host a conference call on Thursday, November 2, 2017, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International).  The conference ID number is 8498419.  The live audio webcast can be accessed via the Investor Relations' section of Apricus' website at www.apricusbio.com.  Please log in approximately 5-10 minutes before the event to ensure a timely connection.  The archived webcast will remain available for 30 days following the live call.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which we own worldwide rights.

For further information on Apricus, visit http://www.apricusbio.com.

Vitaros^(TM) is Apricus' trademark in the United States, which is pending registration and subject to the agreement with Allergan.  Vitaros^® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States.  RayVa^(TM) is Apricus' trademark, which is registered in certain countries throughout the world and pending registration in the United States.

CONTACT:    
Matthew Beck
[email protected]
The Trout Group
(646) 378-2933